Impact of Recombinant Humanized Type III Collagen on the Immediate and Long-term Effects of Breast Tumor Surgery

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2028

Conditions
Breast CancerCollagen Protein
Interventions
BIOLOGICAL

Recombinant Humanized Type III Collagen Injection

rhCOL3/saline will be injected around the tumor (at four points: outer upper, inner upper, outer lower, and inner lower) before surgery, with 500ul per site. After the surgical margin is confirmed to be safe by rapid frozen pathology during surgery, a second injection of 2ml will be administered around the surgical area skin (at points spaced along the skin incision), followed by routine tissue flap revision and suture.

Trial Locations (1)

100044

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER